Zydus and Lupin Collaborate to Distribute Semaglutide Weight-Loss Injections for Diabetes Care in India

Zydus Lifesciences Enters Licensing Deal with Lupin Limited

Zydus Lifesciences, a leading pharmaceutical company, has announced a licensing and supply agreement with Lupin Limited to expand the availability of Semaglutide Injection, a diabetes medication, in India. The deal grants Lupin semi-exclusive rights to co-market Zydus' innovative Semaglutide Injection in the Indian market under the brand names Semanext and Lupin's Livarise.

Key Terms of the Deal

• Lupin will pay an initial licensing fee to Zydus along with milestone-based payments upon reaching specific targets.
• The partnership aims to enhance patient reach for cutting-edge diabetes care and chronic weight management solutions.
• Zydus will market the product under the brand names Semaglyntm, Mashematm, and Altermetm.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Innovative Pen Device

The partnership focuses on making therapy simpler for patients through the use of an innovative pen device. This reusable pen device is designed to improve quality of life for patients receiving the treatment.

Additional Developments

• Zydus has received approval from China's National Medical Products Administration (NMPA) for its novel medication, Desidustat tablets, for the treatment of renal anaemia.
• Desidustat is an oral therapy designed to manage anaemia in Chronic Kidney Disease (CKD) patients.
• The approval marks a significant milestone in Zydus' efforts to improve patient outcomes and expand its global presence.

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year